{
    "clinical_study": {
        "@rank": "85850", 
        "arm_group": {
            "arm_group_label": "Dabrafenib, Trametinib and Metformin", 
            "arm_group_type": "Experimental", 
            "description": "Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "The main purpose is to evaluate the clinical response, safety and survival of the FDA\n      approved drugs Dabrafenib, Trametinib in combination with Metformin.  Investigators\n      hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with\n      the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity\n      and improve clinical outcomes in terms of objective response rates and survival in\n      metastatic melanoma patients."
        }, 
        "brief_title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "The study will be a single-arm, single center, uncontrolled phase I/II trial to estimate the\n      safety of the combined treatments and then estimate the efficacy in terms of objective\n      response rate in patients with stage IIIC and Stage IV melanoma treated with\n      dabrafenib/trametinib and metformin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients > 18 years of age\n\n          -  Patients with histologically confirmed BRAFV600E melanoma (Stage IIIC or\n\n          -  Stage IV, American Joint Commission on Cancer)\n\n          -  Eastern Cooperative Oncology Group Performance Status of 0 to 2\n\n          -  Life expectancy > 3 months\n\n          -  At least 1 site of radiographically measurable disease by RECIST 1.1\n\n          -  Adequate hematologic, renal, and liver function as defined by laboratory values\n             performed within 42 days prior to initiation of dosing:\n\n          -  Absolute neutrophil count > 1.0 x 10\u2079/L\n\n          -  Platelet count > 50 x 10\u2079/L\n\n          -  Hemoglobin >  8 g/dL\n\n          -  Serum creatinine < 2 x upper limit of normal\n\n          -  Total serum bilirubin < 3 x ULN\n\n          -  Serum aspartate transaminase or serum alanine transaminase < 3 x ULN, and < 4 x ULN\n             if liver metastases are present\n\n          -  Fertile males should use an effective method of contraception during treatment and\n             for at least 3 months after completion of treatment, as directed by their physician\n\n          -  Pre-menopausal females and females < 2 years after the onset of menopause should have\n             a negative pregnancy test at Screening.  Pre-menopausal females must agree to use an\n             acceptable method of birth control from the time of the negative pregnancy test up to\n             90 days after the last dose of the study drug\n\n          -  Females of non-childbearing potential may be included if they are either surgically\n             sterile or have been postmenopausal for > 1 year\n\n          -  Before study entry, written informed consent must be obtained from the patient prior\n             to performing any study related procedures\n\n        Exclusion Criteria:\n\n          -  Prior treatment with Vemurafenib or Dabrafenib\n\n          -  Known hypersensitivity to Metformin or any of its components\n\n          -  Received radiotherapy for non CNS disease within the 2 weeks prior to commencing\n             study treatment or have not recovered from side effects of all radiation related\n             toxicities to Grade < 1, except for alopecia\n\n          -  Pregnant, breast feeding, or refusing double barrier contraception, oral\n             contraceptives, or avoidance of pregnancy measures\n\n          -  Have any other uncontrolled infection or medical condition that could interfere with\n             the conduct of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143050", 
            "org_study_id": "BCC-MEL-14-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dabrafenib, Trametinib and Metformin", 
                "intervention_name": "Dabrafenib", 
                "intervention_type": "Drug", 
                "other_name": "Tafinlar"
            }, 
            {
                "arm_group_label": "Dabrafenib, Trametinib and Metformin", 
                "intervention_name": "Trametinib", 
                "intervention_type": "Drug", 
                "other_name": "Mekinist"
            }, 
            {
                "arm_group_label": "Dabrafenib, Trametinib and Metformin", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Unresectable melanoma Stage IIIC and Stage IV BRAF V600E+", 
        "lastchanged_date": "May 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jason.chesney@louisville.edu", 
                    "last_name": "Jason A Chesney, MD, PhD", 
                    "phone": "502-562-3429"
                }, 
                "contact_backup": {
                    "email": "christy.laduke@louisville.edu", 
                    "last_name": "Christina LaDuke", 
                    "phone": "502-217-5205"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "James Graham Brown Cancer Center-Universityof Louisville"
                }, 
                "investigator": [
                    {
                        "last_name": "Donald M Miller, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kelly M McMasters, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sucheta Telang, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kmcart05@louisville.edu", 
                    "last_name": "Karen Carter, BSN", 
                    "phone": "502-562-3690"
                }, 
                "contact_backup": {
                    "email": "christi.laduke@louisville.edu", 
                    "last_name": "Christina LaDuke, BS", 
                    "phone": "502-217-5205"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "James Graham Brown Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients", 
        "overall_contact": {
            "email": "msbaum02@louisville.edu", 
            "last_name": "Stacy Baum, BSN", 
            "phone": "502-562-2280"
        }, 
        "overall_contact_backup": {
            "email": "kmcart05@louisville.edu", 
            "last_name": "Karen Carter, BSN", 
            "phone": "502-562-3690"
        }, 
        "overall_official": {
            "affiliation": "James Graham Brown Cancer Center", 
            "last_name": "Jason A Chesney, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "During phase I, six patients will be enrolled and monitored for toxicities.  If drug related deaths occur or more than two drug related CTCAE grade 4 toxicities occur the trial will be suspended. Phase II will estimate the efficacy of the drugs, enrolling  20 patients during stage 1 with an upper limit of 39 for the 2nd stage.", 
                "measure": "Observation of two CTCAE drug related grade 4 toxicities in six patients.", 
                "safety_issue": "Yes", 
                "time_frame": "Duration of phase I portion, approxiately 6 months"
            }, 
            {
                "description": "Phase II will study the efficacy of the drugs enrolling 20 patients during stage I with an upper limit of 39 for the 2nd stage.", 
                "measure": "Clinical Response Rate", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143050"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will be contacted every 3 months following treatment administration for up to three years to obtain survival data.", 
                "measure": "To estimate the overall survival rates.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "description": "To identify demographic, disease and treatment related effects on overall survival.", 
                "measure": "To explore the effect of other covariates on overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "James Graham Brown Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Louisville", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "James Graham Brown Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}